R. Sharkey

D. Goldenberg, R. Sharkey, C. Motta-Hennessy, 1991, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

Selection of a dtpa chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice

M. Brechbiel, G. Griffiths, O. Gansow, 1990, International journal of cancer.

Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.

D. Goldenberg, R. Sharkey, F. Kaltovich, 1988, Cancer research.

Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.

V. Rohmer, F. Kraeber-Bodéré, S. Bardet, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimization of Hapten-Peptide Labeling for Pretargeted ImmunoPET of Bispecific Antibody Using Generator-Produced 68Ga

W. Mcbride, D. Goldenberg, R. Sharkey, 2011, The Journal of Nuclear Medicine.

Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial.

J. Berlin, A. Bardia, J. Lang, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.

A. Bardia, D. Juric, Q. Hong, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors

O. Boerman, D. Goldenberg, R. Sharkey, 1992, International journal of cancer.

Phase I/II Clinical Radioimmunotherapy with an Iodine-131 -Labeled Anti-Carcinoembryonic Antigen

Y. Vardi, M. Juweid, D. Goldenberg, 1997 .

Localization by immunoperoxidase and estimation by radioimmunoassay of carcinoembryonic antigen in colonic polyps.

D. Goldenberg, R. Sharkey, P. Hagihara, 1977, British Journal of Cancer.

Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts.

D. Goldenberg, R. Sharkey, G. Wong, 1994, Cancer research.

Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

M. Campone, F. Kraeber-Bodéré, D. Goldenberg, 2020, The Journal of Nuclear Medicine.

Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.

M. Juweid, D. Goldenberg, J. Siegel, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Can occult metastases be Treated by radioimmunotherapy?

M. Juweid, D. Goldenberg, R. Sharkey, 1997, Cancer.

Antibody penetration of tumor GS-7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colon.

K. Klein, D. Goldenberg, R. Sharkey, 1996, Cancer research.

Metastatic Human Colonic Carcinoma: Molecular Imaging with PretargetedSPECTandPETina

S. Vallabhajosula, W. Mcbride, D. Goldenberg, 2008 .

Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.

S. Vallabhajosula, W. Mcbride, D. Goldenberg, 2008, Radiology.

Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.

S. Larson, W. Mcbride, D. Goldenberg, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods

W. Mcbride, D. Goldenberg, R. Sharkey, 2005, Clinical Cancer Research.

Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.

M. Juweid, D. Goldenberg, J. Siegel, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recent progress in cancer therapy with radiolabeled monoclonal antibodies.

D. Goldenberg, R. Sharkey, 2011, Therapeutic delivery.

Radioimmunotherapy against the tumor vasculature: A new target?

R. Sharkey, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioactive Antibodies: A Historical Review of Selective Targeting and Treatment of Cancer

D. Goldenberg, R. Sharkey, 2010, Hospital practice.

Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)

M. Czuczman, D. Goldenberg, R. Sharkey, 2008, Clinical Cancer Research.

Radioactive antibodies: Selective targeting and treatment of cancer and other diseases

J. Chatal, D. Goldenberg, J. Barbet, 2007, Applied Radiology.

Radioimmunotherapy of non-Hodgkin's lymphoma revisited.

D. Goldenberg, R. Sharkey, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.

W. Mcbride, D. Goldenberg, R. Sharkey, 2008, Cancer research.

90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.

G. Griffiths, D. Goldenberg, R. Sharkey, 1998, Bioconjugate chemistry.

Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4.

R. Sharkey, D. Gold, R. Alisauskas, 1995, Cancer research.

Haematological effects of radioimmunotherapy in cancer patients

D. Goldenberg, R. Sharkey, R. Stein, 1992, British journal of haematology.

Changes in tumor vascular permeability in response to experimental radioimmunotherapy: a comparative study of 11 xenografts.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1998, Experimental hematology.

Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.

W. Hiddemann, B. Wörmann, M. Béhé, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.

W. McBride, J. Chatal, D. Goldenberg, 2002, Molecular cancer therapeutics.

Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.

G. Griffiths, D. Goldenberg, R. Sharkey, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody

W. Mcbride, D. Goldenberg, R. Sharkey, 2005, Leukemia.

99Tcm-LL1: A potential new bone marrow imaging agent

D. Goldenberg, R. Sharkey, H. Hansen, 1997, Nuclear medicine communications.

Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.

W. Mcbride, S. Litwin, D. Goldenberg, 2008, Cancer research.

Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft

W. Mcbride, D. Goldenberg, R. Sharkey, 2005, Clinical Cancer Research.

Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.

S. Kennel, D. Goldenberg, J. Siegel, 1992, Cancer research.

Defining the optimal spacing between repeat radioantibody doses in experimental models

M. Juweid, D. Goldenberg, R. Sharkey, 1997, Cancer.

Phase I clinical evaluation of a new murine monoclonal antibody (mu‐9) against colon‐specific antigen‐p for targeting gastrointestinal carcinomas

D. Goldenberg, J. Siegel, R. Sharkey, 1994, Cancer.

Prospects for Cancer Imaging and Therapy with Radioimmunoconjugates

D. Goldenberg, R. Sharkey, R. Blumenthal, 1994 .

Influence of animal host and tumor implantation site on radio‐antibody uptake in the GW‐39 human colonic cancer xenograft

D. Goldenberg, R. Sharkey, R. Blumenthal, 1989, International journal of cancer.

Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1991, Journal of the National Cancer Institute.

Localization by whole-body autoradiography of intact and fragmented radiolabeled antibodies in a metastatic human colonic cancer model.

D. Goldenberg, R. Sharkey, I. Fand, 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.

M. Pykett, D. Goldenberg, J. Siegel, 1987, Cancer research.

Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.

D. Goldenberg, R. Sharkey, E. Rossi, 2010, Cancer biotherapy & radiopharmaceuticals.

Biological Considerations for Radioimmunotherapy1

D. Goldenberg, R. Sharkey, H. Hansen, 2006 .

Radioimmunotherapy of Human Colonie Cancer Xenografts with 90 Y-labeled Monoclonal Antibodies to Carcinoembryonic Antigen 1

D. Goldenberg, R. Sharkey, F. Kaltovich, 2006 .

Biological Considerations for Radioimmunotherapy 1

D. Goldenberg, R. Sharkey, H. Hansen, 2006 .

Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p

D. Goldenberg, R. Sharkey, R. Blumenthal, 2005, Cancer Immunology, Immunotherapy.

Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor

O. Boerman, D. Goldenberg, R. Sharkey, 2005, Cancer Immunology, Immunotherapy.

The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: An autoradiographic study

O. Boerman, D. Goldenberg, R. Sharkey, 2005, Cancer Immunology, Immunotherapy.

Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens.

D. Goldenberg, R. Sharkey, H. Hansen, 1990, Cancer research.

Comparison of therapeutic efficacy and host toxicity of two different 131I‐labelled antibodies and their fragments in the GW‐39 colonic cancer xenograft model

D. Goldenberg, R. Sharkey, R. Blumenthal, 1989, International journal of cancer.

Imaging of colorectal carcinoma with radiolabeled antibodies.

D. Goldenberg, R. Sharkey, H. Hansen, 1989, Seminars in nuclear medicine.

Reduction of radioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1.

D. Goldenberg, R. Sharkey, H. Hansen, 1988, Cancer research.

Antibody protein dose and radioimmunodetection of gw‐39 human colon tumor xenografts

D. Goldenberg, R. Sharkey, F. J. Primus, 1987, International journal of cancer.

Quantitative whole-body autoradiography of radiolabeled antibody distribution in a xenografted human cancer model.

K. Yamamoto, A. Brill, D. Goldenberg, 1986, Cancer research.

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients

O. Couturier, C. Bodet-Milin, F. Kraeber-Bodéré, 2015, Front. Med..

Successful Radioimmuno-therapy for Lung Metastasis of Human Colonic Cancer in Nude Mice

D. Goldenberg, R. Sharkey, R. Blumenthal, 1991 .

Characterization of second‐generation monoclonal antibodies against carcinoembryonic antigen

D. Goldenberg, R. Sharkey, H. Hansen, 1993, Cancer.

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

A. Alavi, M. Czuczman, F. Kraeber-Bodéré, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.

M. Juweid, R. Sharkey, H. Hansen, 1995, Cancer research.

A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.

D. Goldenberg, R. Sharkey, J. Burton, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.

M. Juweid, G. Griffiths, D. Goldenberg, 1995, Cancer research.

Pretargeting: Advancing the Delivery of Radionuclides

D. Goldenberg, R. Sharkey, 2013 .

Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.

D. Goldenberg, J. Siegel, R. Sharkey, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Labeled Humanized Anti-CEA Monoclonal Antibody with Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer

D. Goldenberg, R. Sharkey, J. Burton, 2005 .

A human colon cancer metastasis model for radioimmunodetection.

D. Goldenberg, R. Sharkey, F. J. Primus, 1986, Cancer research.

Renal dosimetry: ready for biological effective dose?

J. Siegel, R. Sharkey, M. Stabin, 2010, Cancer biotherapy & radiopharmaceuticals.

Advances in cancer therapy with radiolabeled monoclonal antibodies.

D. Goldenberg, R. Sharkey, 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

A new murine monoclonal antibody against human hepatoma.

K. Klein, D. Goldenberg, R. Sharkey, 1991, Hybridoma.

A pretargeting system for tumor PET imaging and radioimmunotherapy

C. Bodet-Milin, F. Kraeber-Bodéré, J. Chatal, 2015, Front. Pharmacol..

Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.

D. Goldenberg, J. Siegel, R. Sharkey, 1995, Cancer research.

In-vivo antibody imaging for the detection of human tumors.

D. Goldenberg, R. Sharkey, H. Hansen, 1990, Cancer treatment and research.

Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTc.

D. Goldenberg, R. Sharkey, L. C. Swayne, 1990, Cancer research.

Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy.

R. E. Lee, D. Goldenberg, J. Siegel, 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Preclinical evaluation of an "instant" 99mTc-labeling kit for antibody imaging.

A. Jones, D. Goldenberg, M. Buckley, 1990, Cancer research.

Rapid blood clearance of mouse IgG2a and human IgG1 in many nude and nu/+ mouse strains is due to low IgG2a serum concentrations

D. Goldenberg, R. Sharkey, T. Behr, 1998, Cancer Immunology, Immunotherapy.

Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial

V. Rohmer, O. Couturier, C. Bodet-Milin, 2016, The Journal of Nuclear Medicine.

Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts

W. Oyen, W. Mcbride, O. Boerman, 2015, Molecular Imaging and Biology.

Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.

W. Oyen, W. Mcbride, O. Boerman, 2014, Cancer biotherapy & radiopharmaceuticals.

Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody

W. Oyen, W. Mcbride, O. Boerman, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer

W. Oyen, W. Mcbride, O. Boerman, 2012, The Journal of Nuclear Medicine.

New lyophilized kit for rapid radiofluorination of peptides.

W. Mcbride, D. Goldenberg, R. Sharkey, 2012, Bioconjugate chemistry.

Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex.

W. Mcbride, D. Goldenberg, R. Sharkey, 2010, Bioconjugate chemistry.

Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting

W. Mcbride, D. Goldenberg, R. Sharkey, 2007, Journal of Nuclear Medicine.

Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.

W. Mcbride, G. Griffiths, D. Goldenberg, 2000, Bioconjugate chemistry.

Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy.

W. McBride, D. Goldenberg, R. Sharkey, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.

W. Mcbride, G. Griffiths, D. Goldenberg, 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Phase I/II trial of 131I‐MN‐14 F(ab)2 anti–carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

M. Juweid, D. Goldenberg, R. Sharkey, 1999 .

Evaluation of a remote radioiodination system for radioimmunotherapy.

D. Goldenberg, R. Sharkey, K. Weadock, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Experimental model systems for antibody targeting and radioimmunodetection.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1990, Cancer treatment and research.

Use of hematopoietic growth factors to control myelosuppression caused by radioimmunotherapy.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1990, Cancer research.

The advantage of residualizing radiolabels for targeting B‐cell lymphomas with a radiolabeled anti‐CD22 monoclonal antibody

D. Goldenberg, R. Sharkey, S. Govindan, 1997, International journal of cancer.

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

Y. Vardi, M. Juweid, D. Goldenberg, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse.

D. Goldenberg, R. Sharkey, C. Motta-Hennessy, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F(ab′)2 antibody

W. Oyen, W. Mcbride, R. Bleichrodt, 2010, Cancer.

anhydride) of DTPA (9) or by attachment ofa reactive group to one of the nitrogen atoms (10). Reaction of the modified chelate with the antibody results in cova

D. Goldenberg, R. Sharkey, C. Motta-Hennessy, 2006 .

Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans.

D. Goldenberg, R. Sharkey, H. Hansen, 1990, Cancer research.

Comparison of tumor targeting of mouse monoclonal and goat polyclonal antibodies to carcinoembryonic antigen in the GW-39 human tumor-hamster host model.

D. Goldenberg, R. Sharkey, F. J. Primus, 1988, Cancer research.

Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.

G. Griffiths, D. Goldenberg, R. Sharkey, 1997, Bioconjugate chemistry.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J. Berlin, A. Bardia, D. Juric, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.

D. Goldenberg, J. Siegel, R. Sharkey, 1996, Cancer research.

PRECLINICAL AND CLINICAL EVALUATION OF A CDR-GRAFTED (HUMANIZED) ANTI-CARCINOEMBRYONIC ANTIGEN (CEA) MONOCLONAL ANTIBODY (MAb)

M. Juweid, G. Griffiths, D. Goldenberg, 1994 .

Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.

A. Alavi, D. Goldenberg, R. Sharkey, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

D. Goldenberg, R. Sharkey, R. Stein, 2018, Oncotarget.

Lymphoma imaging with a new technetium-99m labelled antibody, LL2

D. Goldenberg, R. Sharkey, H. Hansen, 2004, European Journal of Nuclear Medicine.

The direct route may not be the best way to home.

R. Sharkey, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?

W. McBride, J. Chatal, D. Goldenberg, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.

F. Kraeber-Bodéré, A. Devillers, J. Chatal, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The radiolabeling of proteins by the [18F]AlF method.

W. Mcbride, D. Goldenberg, R. Sharkey, 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion.

Wendy S. Becker, M. Juweid, D. Goldenberg, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Suppression of tumor vascular activity by radioantibody therapy: implications for multiple cycle treatments.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1991, Selective cancer therapeutics.

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

P. Schwartz, D. Goldenberg, R. Sharkey, 2018, Gynecologic oncology reports.

Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice

D. Goldenberg, R. Sharkey, R. Blumenthal, 1997, International journal of cancer.

Structure and functional reconstitution of the sodium channel from rat brain.

W. Catterall, M. Tamkun, R. Sharkey, 1984, Biophysical journal.

Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.

M. Juweid, D. Goldenberg, J. Siegel, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A Novel Facile Method of Labeling Octreotide with 18F-Fluorine

W. Oyen, W. Mcbride, A. Eek, 2010, Journal of Nuclear Medicine.

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

J. Hajdenberg, B. Faltas, S. Tagawa, 2016, Clinical genitourinary cancer.

Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody

W. Oyen, O. Boerman, W. M. van Weerden, 2011, The Journal of Nuclear Medicine.

Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.

M. Juweid, D. Goldenberg, R. Sharkey, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.

M. Juweid, G. Griffiths, D. Goldenberg, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Blood-based red marrow dosimetry: where's the beef?

B. Wessels, W. Bolch, J. Siegel, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Rapid Blood Clearance of Immunoglobulin G 2 a and Immunoglobulin G 2 b in Nude Mice 1

D. Goldenberg, R. Sharkey, A. Natale, 2006 .

Rapid blood clearance of immunoglobulin G2a and immunoglobulin G2b in nude mice.

D. Goldenberg, R. Sharkey, A. Natale, 1991, Cancer research.

Use of whole-body autoradiography in cancer targeting with radiolabeled antibodies.

D. Goldenberg, R. Sharkey, I. Fand, 1990, Cancer research.

Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.

W. Oyen, W. Mcbride, D. Goldenberg, 2014, Bioconjugate chemistry.

Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.

A. Alavi, D. Porter, D. Goldenberg, 2003, Clinical lymphoma.

Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation.

D. Goldenberg, R. Sharkey, J. Hess, 1995, Experimental hematology.

Cytokine Intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL‐1/GM‐CSF

D. Goldenberg, R. Sharkey, G. Wong, 1994, Cancer.

Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer.

W. Oyen, W. Mcbride, O. Boerman, 2014, Cancer research.

Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1990, Seminars in cancer biology.

A fluorouridine‐anti‐CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model

D. Goldenberg, R. Sharkey, H. Xuan, 1990, International journal of cancer.

Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): First results

W. Oyen, W. McBride, O. Boerman, 2011 .

A new tri-Fab recombinant bispecific antibody (bsMAb) for pretargeting epithelial cancers: Studies with TF12 and 111In-labeled hapten-peptide (IMP 288) in ovarian cancer

D. Goldenberg, R. Sharkey, E. Rossi, 2010 .

Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.

W. Mcbride, G. Griffiths, D. Goldenberg, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.

W. Mcbride, G. Griffiths, D. Goldenberg, 2002, Bioconjugate chemistry.

Biological considerations for radioimmunotherapy.

D. Goldenberg, R. Sharkey, H. Hansen, 1990, Cancer research.

Physiological factors influencing radioantibody uptake: A study of four human colonic carcinomas

D. Goldenberg, R. Sharkey, R. Blumenthal, 1992, International journal of cancer.

Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients.

D. Goldenberg, R. Sharkey, H. Hansen, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Structure determination of N-linked oligosaccharides engineered at the CH1 domain of humanized LL2.

D. Goldenberg, R. Sharkey, H. Hansen, 1997, Glycobiology.

Radiolabeled antibodies as in-vivo cancer probes (review).

R. Sharkey, D. Goldenberg, 1993, International journal of oncology.

Conjugation of phenyl isothiocyanate derivatives of carborane to antitumor antibody and in vivo localization of conjugates in nude mice.

M. Hawthorne, D. Goldenberg, R. Sharkey, 1991, Bioconjugate chemistry.

A Divalent Hapten-Peptide Induces Apoptosis in Human Non–Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 × Anti-Hapten Bispecific Antibodies

W. Mcbride, D. Goldenberg, R. Sharkey, 2007, Clinical Cancer Research.

Hapten-Peptide Induces Apoptosis in Human Non ^ Hodgkin Lymphoma Cell Lines Targeted by Anti-CD 20 Anti-Hapten Bispecific Antibodies

W. Mcbride, D. Goldenberg, R. Sharkey, 2007 .

Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.

W. Mcbride, G. Griffiths, D. Goldenberg, 1997, Bioconjugate chemistry.

Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.

M. Juweid, D. Goldenberg, R. Sharkey, 1997, Gynecologic oncology.

Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies.

D. Goldenberg, R. Sharkey, L. C. Swayne, 1997, Surgery.

Optimized labeling of NOTA-conjugated octreotide with F-18

W. Oyen, W. Mcbride, A. Eek, 2011, Tumor Biology.

A Novel Method of 18F Radiolabeling for PET

W. Mcbride, O. Boerman, D. Goldenberg, 2009, Journal of Nuclear Medicine.

Carcinoembryonic antigen in carcinoma of the uterine cervix 2. Tissue localization and correlation with plasma antigen concentration

R. Sharkey, F. J. Primus, J. van Nagell, 1979, Cancer.

Carcinoembryonic Antigen and a-Fetoprotein Expression and Monoclonal Antibody Targeting in a Human Hepatoma/Nude Mouse Model1

D. Goldenberg, R. Sharkey, R. Stein, 2006 .

Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens

D. Goldenberg, R. Sharkey, F. J. Primus, 1978, Cancer.

Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1992, Journal of the National Cancer Institute.

Anti-antibody enhancement of tumor imaging.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1990, Cancer treatment and research.

Comparative biodistribution and radioimmunotherapy of monoclonal antibody rs7 and its f(ab′)2 in nude mice bearing human tumor xenografts

D. Goldenberg, R. Sharkey, R. Blumenthal, 1994, Cancer.

Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections.

D. Goldenberg, R. Sharkey, F. J. Primus, 1976, Journal of the National Cancer Institute.

The prognostic significance of carcinoembryonic antigen in the plasma and tumors of patients with endometrial adenocarcinoma.

D. Goldenberg, R. Sharkey, J. van Nagell, 1977, American journal of obstetrics and gynecology.

Improved Targeting of Pancreatic Cancer

D. Goldenberg, D. Modrak, R. Sharkey, 2004, Clinical Cancer Research.

Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts.

D. Goldenberg, J. Siegel, R. Sharkey, 1990, Cancer research.

Pretargeted Radioimmunotherapy of Cancer

R. Sharkey, D. Goldenberg, 2010 .

Factors influencing anti-antibody enhancement of tumor targeting with antibodies in hamsters with human colonic tumor xenografts.

D. Goldenberg, R. Sharkey, J. Mabus, 1988, Cancer research.

A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2–Expressing Epithelial Cancers

Chien-Hsing Chang, Edmund A. Rossi, Robert M. Sharkey, 2012, The Journal of Nuclear Medicine.

Selection of radioimmunoconjugates for the therapy of well‐established or micrometastatic colon carcinoma

G. Griffiths, D. Goldenberg, R. Sharkey, 1997, International journal of cancer.

Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method

W. Oyen, W. Mcbride, O. Boerman, 2012, EJNMMI Research.

Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.

M. Juweid, D. Goldenberg, R. Sharkey, 1997, Journal of nuclear medicine technology.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

R. Korn, D. V. Von Hoff, M. Lowery, 2015, European journal of cancer.

Perspectives on cancer therapy with radiolabeled monoclonal antibodies.

D. Goldenberg, R. Sharkey, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results

W. Oyen, W. Mcbride, O. Boerman, 2013, British Journal of Cancer.

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.

D. Goldenberg, J. Siegel, R. Sharkey, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of antibodies and immunoconjugates for the therapy of more accessible cancers.

D. Goldenberg, R. Sharkey, 2008, Advanced drug delivery reviews.

Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies.

R. DeJager, D. Goldenberg, M. Monestier, 1990, Cancer research.

Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.

M. Béhé, D. Goldenberg, C. Apostolidis, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

R. Heist, D. Camidge, W. Messersmith, 2017, Clinical Cancer Research.

Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments.

D. Goldenberg, R. Sharkey, T. Behr, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

A. Bardia, H. Rugo, J. Diamond, 2019, The New England journal of medicine.

Radioimmunotherapy of Pancreatic Adenocarcinoma

D. Goldenberg, R. Sharkey, D. Gold, 2013 .

Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

A. Bardia, W. Messersmith, P. Maliakal, 2017, Cancer.

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.

D. Goldenberg, R. Sharkey, S. Govindan, 2015, Bioconjugate chemistry.

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

T. Witzig, D. Goldenberg, R. Sharkey, 2014, Haematologica.

Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.

A. Alavi, D. Goldenberg, R. Sharkey, 2002, Clinical colorectal cancer.

Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodies.

Wendy S. Becker, M. Juweid, D. Goldenberg, 1996, Nuclear medicine communications.

Reduction by anti-antibody administration of the radiotoxicity associated with 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy.

D. Goldenberg, R. Sharkey, R. Blumenthal, 1989, Journal of the National Cancer Institute.

Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer

D. Goldenberg, R. Sharkey, Thomas M Cardillo, 2017, Clinical Cancer Research.

Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).

A. Bardia, D. Juric, J. Diamond, 2018 .

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

J. Berlin, A. Bardia, R. Heist, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer

D. Goldenberg, R. Sharkey, Thomas M Cardillo, 2020, Oncotarget.

Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).

A. Bardia, R. Heist, D. Camidge, 2016 .

Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC

J. Berlin, A. Bardia, T. Traina, 2016 .

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

V. Rohmer, O. Couturier, C. Bodet-Milin, 2021, The Journal of Nuclear Medicine.

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

R. Hauke, D. Goldenberg, R. Sharkey, 2011, Clinical Cancer Research.

IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.

M. Shah, W. Messersmith, P. Maliakal, 2014 .

Antibody-Targeted Therapeutic Radionuclides in the Management of Colorectal Cancer

D. Goldenberg, R. Sharkey, 2013 .

Overcoming the nephrotoxicity of radiometal‐labeled immunoconjugates

Wendy S. Becker, G. Griffiths, D. Goldenberg, 1997, Cancer.

The Dock-and-Lock (DNL) Approach to Novel Bispecific Antibodies

Chien-Hsing Chang, Edmund A. Rossi, Robert M. Sharkey, 2011 .

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.

D. Goldenberg, R. Sharkey, O. Press, 2009, Blood.

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22

M. Juweid, G. Griffiths, D. Goldenberg, 1997, Cancer Immunology, Immunotherapy.

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

R. Elstrom, T. Witzig, D. Goldenberg, 2012 .

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

G. Griffiths, D. Goldenberg, R. Sharkey, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma

W. Mcbride, S. Litwin, D. Goldenberg, 2009, Journal of Nuclear Medicine.

Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates

D. Goldenberg, R. Sharkey, 2006, CA: a cancer journal for clinicians.

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

J. Berlin, R. Goldberg, J. Marshall, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal

D. Goldenberg, R. Sharkey, J. Burton, 2005, Expert review of clinical immunology.

Improving the treatment of non‐Hodgkin lymphoma with antibody‐targeted radionuclides

D. Goldenberg, R. Sharkey, H. Karacay, 2010, Cancer.

Using antibodies to target cancer therapeutics

D. Goldenberg, R. Sharkey, David M Goldenberg, 2012, Expert opinion on biological therapy.

Factors influencing hematologic toxicity of radioimmunotherapy with 131I‐labeled anti‐carcinoembryonic antigen antibodies

M. Juweid, D. Goldenberg, R. Sharkey, 1997, Cancer.

Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10–90Y-IMP-288 Alone and Combined with Gemcitabine

W. Mcbride, D. Goldenberg, R. Sharkey, 2009, Journal of Nuclear Medicine.

Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4.

D. Goldenberg, R. Sharkey, D. Gold, 2001, Critical reviews in oncology/hematology.

Pretargeting of Carcinoembryonic Antigen–Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells

William McBride, Chien-Hsing Chang, W. McBride, 2005, Clinical Cancer Research.

Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.

A. Alavi, M. Juweid, D. Goldenberg, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.

W. Hiddemann, A. Fayyazi, B. Wörmann, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Site‐specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier

D. Goldenberg, R. Sharkey, L. Shih, 1988, International journal of cancer.

Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates.

D. Goldenberg, R. Sharkey, H. Hansen, 1998, Journal of immunological methods.

A universal pretargeting system for cancer detection and therapy using bispecific antibody.

Gary L Griffiths, W. Mcbride, G. Griffiths, 2003, Cancer research.

RADAR Commentary: Evolution and Current Status of Dosimetry in Nuclear Medicine

Michael G Stabin, Jeffry A Siegel, J. Siegel, 2011, The Journal of Nuclear Medicine.

858PSacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results

J. Hajdenberg, E. Lam, M. Galsky, 2017 .

Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study

C. Bailly, C. Bodet-Milin, F. Kraeber-Bodéré, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Immuno-PET using anti-CEA bispecific antibody and 68 Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a First-in Human trial.

Goldenberg, V. Rohmer, O. Couturier, 2016 .

Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An Update

W. Mcbride, D. Goldenberg, R. Sharkey, 2007, Clinical Cancer Research.

Novel radiolabeled antibody conjugates

D. Goldenberg, R. Sharkey, DM Goldenberg, 2007, Oncogene.

Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody

Chien-Hsing Chang, W. Mcbride, D. Goldenberg, 2005, Nature Medicine.

Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.

M. Hawthorne, D. Goldenberg, R. Sharkey, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.

M. Juweid, D. Goldenberg, R. Sharkey, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Rat adjuvant arthritis: imaging with technetium-99m-anti-CD4 Fab' fragments.

F. Emmrich, R. Kinne, D. Goldenberg, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.

M. Juweid, D. Goldenberg, J. Siegel, 1995, Cancer research.

Al18F: A New Standard for Radiofluorination

W. Mcbride, O. Boerman, D. Goldenberg, 2013, The Journal of Nuclear Medicine.

Al18F Labeling of Affibody Molecules

W. Mcbride, D. Goldenberg, R. Sharkey, 2014, The Journal of Nuclear Medicine.

Renal dosimetry in peptide radionuclide receptor therapy.

J. Siegel, R. Sharkey, M. Stabin, 2010, Cancer biotherapy & radiopharmaceuticals.

Application of cytokine intervention for improved radio‐antibody dose delivery

D. Goldenberg, R. Sharkey, T. Behr, 1997, International journal of cancer.

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.

D. Goldenberg, R. Sharkey, M. Pereira, 1999, Cancer.

Renal dosimetry: ready for biological equivalent dose? Response to medical internal radiation dose and European association of nuclear medicine committee letters.

J. Siegel, R. Sharkey, M. Stabin, 2010, Cancer biotherapy & radiopharmaceuticals.

Cancer Therapy : Clinical Treatment of Advanced Pancreatic Carcinoma with 90 Y-Clivatuzumab Tetraxetan : A Phase I Single-Dose Escalation Trial

R. Hauke, D. Goldenberg, R. Sharkey, 2011 .

Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen.

D. Goldenberg, M. Monestier, R. Sharkey, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Initial Clinical Experience with the CDR-grafted (humanized) LL2 anti-CD22 MAb against B-cell malignancies.

A. Alavi, M. Juweid, D. Goldenberg, 1998 .

Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.

A. Bardia, M. Shah, W. Messersmith, 2015 .

In vivo stability and metabolism of 99Tcm-labelled anti-CD4 monoclonal antibodies and Fab' fragments.

F. Emmrich, R. Kinne, D. Goldenberg, 1999, Nuclear medicine communications.

Monoclonal antibody targeting of human non-small cell carcinoma of the lung.

D. Goldenberg, R. Sharkey, R. Stein, 1990, Cancer research.

CARCINO EMBRYONIC ANTIGEN IN OVARIAN EPITHELIAL CYSTADENOCARCINOMAS

R. Sharkey, P. Rayburn, E. Donaldson, 2006 .

Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

D. Goldenberg, R. Sharkey, D. Gold, 2013, Molecular Cancer Therapeutics.

Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

J. Berlin, A. Bardia, J. Diamond, 2015 .

Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

A. Bardia, R. Heist, W. Messersmith, 2015 .

Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience.

J. Berlin, A. Bardia, M. Shah, 2015 .

A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study.

J. Berlin, J. Hecht, J. Marshall, 2015 .

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

D. Goldenberg, R. Sharkey, S. Govindan, 2011, Clinical Cancer Research.

New lyophilized kit for rapid radiofluorination of peptides.

W. Mcbride, D. Goldenberg, R. Sharkey, 2012, Bioconjugate chemistry.

Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer

M. Campone, F. Kraeber-Bodéré, D. Goldenberg, 2020 .

Improving the treatment of non‐Hodgkin lymphoma with antibody‐targeted radionuclides

D. Goldenberg, R. Sharkey, H. Karacay, 2010, Cancer.

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas

R. Sharkey, S. Govindan, Thomas M Cardillo, 2024, OncoTarget.

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

D. Goldenberg, R. Sharkey, S. Govindan, 2020, Oncotarget.